UBS Group Begins Coverage on Kyverna Therapeutics (NASDAQ:KYTX)

UBS Group started coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $13.00 target price on the stock.

Other analysts have also recently issued research reports about the company. Rodman & Renshaw assumed coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a buy rating and a $16.00 target price on the stock. RODMAN&RENSHAW raised Kyverna Therapeutics to a strong-buy rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. reduced their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an overweight rating for the company in a report on Wednesday, July 31st. Finally, HC Wainwright restated a neutral rating and issued a $7.00 price target on shares of Kyverna Therapeutics in a report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Buy and an average price target of $28.71.

Kyverna Therapeutics Price Performance

KYTX opened at $5.25 on Thursday. The business’s fifty day simple moving average is $6.57 and its 200-day simple moving average is $11.24. Kyverna Therapeutics has a 12-month low of $4.40 and a 12-month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Monday, August 12th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.03. Equities analysts predict that Kyverna Therapeutics will post -3.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of large investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale acquired a new stake in Kyverna Therapeutics in the 1st quarter worth approximately $181,000. Creative Planning acquired a new stake in shares of Kyverna Therapeutics during the third quarter worth $54,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Kyverna Therapeutics during the first quarter valued at $313,000. Federated Hermes Inc. acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at $120,000. Finally, Rhumbline Advisers purchased a new position in Kyverna Therapeutics in the 2nd quarter worth $150,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.